Clinical Trial Detail

NCT ID NCT02903368
Title Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Leuprolide + Prednisone

Abiraterone + Apalutamide + Leuprolide + Prednisone

Age Groups: adult senior

No variant requirements are available.